Incyte Corp (INCY)
$88.32 1.40 (1.61%)
11:17 EDT INCY Stock Quote Delayed 15 Minutes
Previous Close $86.92
Market Cap 18.72B
PE Ratio -116.21
Volume (Avg. Vol.) 297,344
Day's Range 86.33 - 88.63
52-Week Range 57.00 - 89.30
Dividend & Yield N/A (N/A)
INCY Stock Predictions, Articles, and Incyte Corp News
- From InvestorPlace
- From the Web
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
The stock charts of COG, INCY and SRE are worth a closer technical look at the midpoint of the trading week.
The stock charts of PFE, INCY and MGM are finally making good on previously-suggested promise.
The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.
The stock charts of SLG, INCY and ETR are shaping up as the best trading bets as the new week kicks off.
Incyte (INCY) was falling hard on Friday following news of a failed Phase 3 drug trial for its melanoma drug epacadostat.
If you’re itching to buy, avoid these stocks at all costs. Here's what makes them stocks to sell for all wise investors.
Biotech stocks had a great run in 2017. The new year could have more big gains ahead. Here are 5 top biotech stocks to buy today.
Incyte Corp (NASDAQ:INCY) is a $22.2 billion in market value member of the Biotechnology GICS industry group where Portfolio Grader's current ranking for INCY puts it 171 among the 349 companies in this industry group, placing it in the top half. INCY is ranked in the third quartile of the sector with a ranking of 402 among the 785 companies in the sector and number 2,601 in the 5000 company Portfolio Grader company universe.
Toxic stocks are exposed to outside shocks and are burdened with high levels of debts. Also, the price of toxic stocks is artificially inflated.
Biotech stocks are surging amid M&A speculation after Gilead agreed to buy Kite Pharma. And these biotechs are moving higher in response.
From Real Money
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!